What adjuvant therapy would you offer an elderly but healthy patient with T2N1 HR+ HER2+ breast cancer who is not willing to receive cytotoxic chemotherapy?  

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at NYU Winthrop Hospital
After Trastuzumumab, I will continue A/I for 5-10 ...
Sign in or Register to read more